Clemens Jakobi joined Lonza in 2018 and took over the Commercial Development responsibility for Lonza’s Large-scale Microbial Modality Offering. During his tenure, he drove several growth initiatives including the expansion of the Microbial Mid-scale Capabilities. As a member of the IBEX team, he then provided innovative manufacturing solutions to customers world-wide. In 2021, Clemens joined the mRNA Business Unit and drove the commercial activities enabling the Expansion of Lonza’s mRNA services at Lonza’s site in Geleen, the Netherlands.
Clemens held technical and commercial leadership roles in the Pharma Industry before transitioning to Lonza. He is a certified in Switzerland as a Pharmacist, holds a Ph.D. degree in Biology from the University of Freiburg, Germany, and graduated from the State University of New York at Albany as a Master of Business Administration. In his free time, he supports innovation in Switzerland as a member and president of the Swiss Excellence Foundation.